

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Synthesis of 7-Alkylidene-7,12-dihydroindolo[3,2-*d*]benzazepine-6-(5*H*)-ones (7-Alkylidene-Paullones) by *N*-cyclization-Oxidative Heck Cascade and Characterization as Sirtuin Modulators†

J. G. Denis,^a G. Franci,^b L. Altucci,^b J. M. Aurrecochea,^c Á. R. de Lera,^{*,a} and R. Álvarez^{*,a}

Received (in XXX, XXX) Xth XXXXXXXXX 200X, Accepted Xth XXXXXXXXX 200X

First published on the web Xth XXXXXXXXX 200X

DOI: 10.1039/b000000x


An extension of our reported protocol to benzofused heterocyclic derivatives (benzofurans, indoles, isochromeneimines), involving a palladium-induced cascade of *N*-cyclization and oxidative Heck reactions of *o*-alkynylanilines, has allowed the preparation of indolobenzazepinones (paullones) with an alkylidene group at C7 in just 3-4 steps from *ortho*-iodoanilines. Some of these compounds behave as Sirt1 activators in biochemical assays.

Introduction

Compounds with the 7,12-dihydroindolo[3,2-*d*]benzazepine-6(5*H*)-one scaffold represented by **1a**, collectively known as paullones, are endowed with a broad range of biological activities. They have been characterized as inhibitors of several kinases,¹ and of mitochondrial malate dehydrogenase (mMDH).² Some of the members of the group, in particular the C9-Br derivative (kenpaullone, **1b**) and analogues **2** and **3** have been reported to also target the NAD⁺-dependent class of histone deacetylases (sirtuins, Sirt).³ In addition, kenpaullone **1b** has been established as a chemical probe in stem-cell research.⁴ Cytotoxic,⁵ antiproliferative,⁶ and pro-apoptotic^{1b,7} effects of paullones have been noted in human cancer cell lines, rendering these compounds as promising antitumor agents.⁸ Additionally, paullones have been considered as therapeutic agents for trypanosomiasis and leishmaniasis,⁹ and selected members of the family (cazpaullone **1c** and alsterpaullone **1d**)¹⁰ for the treatment of diabetes since they suppress cytokine induced β -cell apoptosis.¹¹

These promising biological activities have raised the interest in these compounds and have stimulated the development of synthetic methodologies to prepare analogues retaining the basic 7,12-dihydroindolo[3,2-*d*]benzazepine-6(5*H*)-one scaffold. In addition to the classical construction of the fused 1*H*-indole moiety by Fischer indolization reactions,^{1b,2,6,9b} a variety of other methods have been reported, among them the free radical cyclisation of indolyl iodoacetamide derivatives,¹² and the photocyclization of 2-(2-chloro-1*H*-indol-3-yl)-*N*-arylacetamides.¹³ Transition-metal mediated processes have likewise provided solutions for some of the steps in the construction of the basic paullone skeleton. Notable among them are the intramolecular Heck reaction,¹⁴ an oxidative coupling after rhodium(III)-catalyzed C-H functionalization of acetamides with alkynes,¹⁵ the Pd-promoted borylation/Suzuki coupling and lactam formation,¹⁶ the Cu(I)-catalyzed borylative cyclization of

2-alkenylphenyl isocyanides,¹⁷ the free radical formation of stannylindoles from *o*-alkenyl arylisonitriles and subsequent Stille cross-coupling with *N*-Boc-*o*-iodoanilines,¹⁸ the combined Heck and Stille reactions,¹⁹ and the one-pot Suzuki-Miyaura cross-coupling of an *o*-aminoarylboronic acid and methyl 2-iodoindoleacetate followed by intramolecular amide formation reported by our group.²⁰




1a, X = H, Y = CH, Paullone
1b, X = Br, Y = CH, Kenpaullone
1c, X = CN, Y = N, Cazpaullone
1d, X = NO₂, Y = CH, Alsterpaullone

2, *N*-Benzylkenpaullone

3, Kenpaullone hydroxyamidine

Figure 1. Biologically-relevant 7,12-dihydroindolo[3,2-*d*]benzazepine-6(5*H*)-ones (paullones).


We have developed a new synthetic methodology that streamlines the preparation of benzofurans,²¹ indoles^{22,21c} and other heterocyclic derivatives^{21b-c,22,23} starting from the corresponding *o*-iodoaryl precursors. This sequential process combined a Pd-catalyzed Sonogashira cross-coupling and a nucleopalladation-Heck oxidative reaction (Scheme 1). Moreover, the protocol was also performed as a "one-pot" process where the Sonogashira and oxidative steps were combined in a three-component Sonogashira-heterocyclization-Heck-coupling cascade.^{21c}



Scheme 1. Our synthetic approach to benzofurans and indoles, including the intramolecular version.

We envisioned that the intramolecular variant of this synthetic procedure^{21b,c} could be extended to the preparation of additional paullone analogues featuring an exocyclic olefin at


the C7 position (general structure **4**, Scheme 2) of the benzazepine-6(*5H*)-one ring, a modification that has no precedents to the best of our knowledge. To integrate this substitution pattern into the structures shown in Figure 1, a precursor **5** containing an alkyne substituted with aryl rings that bear an *o*-amino and an *o*'-acylamino groups were required. Two consecutive Sonogashira reactions via **7** would trace back the cyclising substrate **5** to simple, and in most cases commercial, *o*-haloanilines **6** (Scheme 2; for the meaning of X, R, Z, see Scheme 3).



Scheme 2. Retrosynthetic analysis of C7-alkydenepaullones using a Pd-catalyzed *N*-cyclization-intramolecular oxidative Heck cascade reaction.

Results and discussion

After surveying all synthetic variants for the preparation of the *N*-differentiated *o*,*o*'-bisaniline-ethyne substrates **5** (see Supplementary Information, S. I.) we selected the order of steps shown in Scheme 3 comprising first the acylation of an *o*-alkynyl aniline and then the Sonogashira reaction with an appropriate *o*-iodoaniline. The condensation of 2-ethynylaniline **8** with acryloyl chloride,²⁴ was followed by the Sonogashira reaction^{21,22} of product **7a** with commercial *o*-iodoaniline **6a** to afford in quantitative yield the corresponding internal alkyne **5aa**. Excellent yields were obtained in all steps of the synthetic route. The same sequence was used for the preparation of the remaining substrates **5** as shown in Scheme 3.



Scheme 3. Reaction conditions: a) Acryloyl chloride, Et₃N, CH₂Cl₂, 25 °C (**7a**, 87%) b) Ethyl (*E*)-4-chloro-4-oxobut-2-enoate, Py, Et₂O, 25 °C (**7b**, 99%). c) ClCO₂Et, K₂CO₃, acetone, 25 °C (**6b**, 99%). d) ClC(O)OEt, Py, ether, 0-10 °C (**6d**, 91%). e) (Boc)₂O, THF, reflux (**6e**, 97%). f) PdCl₂(PPh₃)₂, CuI, Et₃N, THF or DMF, 60 °C (**5aa**, 98%; **5ab**, 99%; **5ac**, 99%; **5ae**, 92%; **5ba**, 76%; **5bb**, 92%; **5bd**, 90%; **5be**, 99%). See Table 1 for the structure of compounds **5**.

Acrylamide **5aa** was treated with 5 mol% PdCl₂(PPh₃)₂, 0.5 equivalents of KI and 1 equivalent of maleic anhydride (MA) in DMF under air, conditions previously developed for nucleopalladation-intramolecular Heck reactions.^{21b,c} When

these conditions were applied at 80 °C, only the 3*H*-indole product **9aa** could be isolated albeit in low yield (18%, Table 1, entry 1). Raising the temperature to 100 °C the desired product **4aa** was obtained in only 14% yield after heating for 24 h (entry 2), being the 3*H*-indole product **9aa** the major component (48%). Shortening the reaction time to 3 h increased the yield of **4aa** to 40% (entry 3), indicating that under the conditions of entry 2, with prolonged heating at high temperature, product degradation was taking place. The substrate with a bromine atom located at the aniline *para* position (compound **5ac**) showed somewhat higher reactivity, and the Pd-catalyzed cascade could be run at 80 °C, to yield **4ac** and **9ac** in a ca. 50:50 ratio (entry 4). Not surprisingly, a temperature increase (entry 5) resulted in a lower yield of **4ac**, again probably due to product degradation.

In the expected cascade reaction mechanism shown in Figure 2, the initial coordination of the *o*-alkynylaniline to Pd(II) triggers nucleopalladation to afford the indole ring and then insertion of the heterocyclic C3-σ-Pd(II) complex into the pendant alkene leads to the olefin product, after β-hydride elimination. The resulting palladium hydride undergoes loss of HCl with formation of Pd(0), which is finally oxidized to regenerate the Pd(II) species that starts the cycle.^{21,22} The 3*H*-indole products **9** are considered to originate from a σ-indolyl-palladium intermediate (**II** or **V**) that undergoes protonation to **VI** (Figure 2).




Figure 2. Mechanistic proposal for the Pd-catalyzed *N*-cyclization-oxidative Heck cascade to alkydenepaullones (Z= H or EWG; L= PPh₃; Y= NH or NCO₂R).

Control experiments revealed that the 3*H*-indole product **9aa** did not undergo C-H activation to enter the catalytic cycle at the level of intermediate **II** (Figure 2) under the reaction conditions. Therefore, it seems reasonable to assume that the


product ratio results from a balance between the rates of carbopalladation with the pendant olefin and protonation of the σ -indolyl intermediate.²⁵ As a result, we tried to modulate the reactivity of the system through the addition of base and the modification of the electronic nature of the olefin and aniline functionalization implicated in the cascade bond formation reactions.

The presence of K_2CO_3 was shown to have a beneficial effect (entries 6-9). Thus, the use of 0.5 mol equivalents induced the total consumption of the reactant and afforded a 76:24 ratio of the benzazepinone to 3*H*-indol (4aa/9aa) mixture in 85%

overall yield (entry 7). Larger amounts of K_2CO_3 proved to be detrimental (entry 8) whereas smaller quantities (entry 6) afforded an almost equal ratio the reaction products in lower yields. The change to NaOAc had no effect (entry 7 vs entry 9).

The introduction of carbonyl substituents at R and/or Z was examined next. Fumarate-derived substrate **5ba** led only to the 3*H*-indole derivative **9ba** in 70% yield (entry 10) under the standard conditions.

Table 1. Nucleopalladation-oxidative Heck cascade for the synthesis of alkylidenepaullones.^a



| entry, substrate | X | R | Z | Reaction conditions | | | Yield (%) | | |
|-----------------------------|----|------------------------------|--------------------|---------------------|-------|-------------------|---------------------------------------|-------------------|--------------------|
| | | | | T (°C) | t (h) | $K_2CO_3^b$ | 4 | 9 | 5 |
| 1, 5aa | H | H | H | 80 | 24 | -- | -- | 18 (9aa) | -- |
| 2, 5aa | H | H | H | 100 | 24 | -- | 14 (4aa) | 48 (9aa) | -- |
| 3, 5aa | H | H | H | 100 | 3 | -- | 40(4aa) | 37 (9aa) | -- |
| 4, 5ac | Br | H | H | 80 | 22 | -- | 50 (4ac) | 50 (9ac) | -- |
| 5, 5ac | Br | H | H | 100 | 22 | -- | 25 (4ac) | 50 (9ac) | -- |
| 6, 5aa | H | H | H | 100 | 3.5 | 0.25 | -- | 28 (9aa) | 28 (5aa) |
| 7, 5aa | H | H | H | 100 | 3.5 | 0.50 | 65 (4aa) | 20 (9aa) | -- |
| 8, 5aa | H | H | H | 100 | 3.5 | 1.00 | 22 (4aa) | <5 (9aa) | -- |
| 9, 5aa | H | H | H | 100 | 3.5 | 0.50 ^c | 34 (4aa) | 30 (9aa) | -- |
| 10, 5ba ^d | H | H | CO ₂ Et | 100 | 24 | -- | -- | 70 (9ba) | -- |
| 11, 5ab | H | CO ₂ Et | H | 80 | 24 | -- | -- | -- | 100 (5ab) |
| 12, 5ab | H | CO ₂ Et | H | 100 | 24 | -- | 52 (4ab) | -- | -- |
| 13, 5bb | H | CO ₂ Et | CO ₂ Et | 100 | 24 | -- | 65 (4bb) | -- | -- |
| 14, 5bb | H | CO ₂ Et | CO ₂ Et | 120 | 24 | -- | 80 (4bb) + 20 (4ba) | -- | -- |
| 15, 5bd | Br | CO ₂ Et | CO ₂ Et | 120 | 20 | -- | 60 ^e (4bd) | -- | -- |
| 16, 5ae | H | CO ₂ <i>t</i> -Bu | H | 120 | 20 | -- | 25 (4ae) + 29 (4aa) | -- | -- |
| 17, 5be | H | CO ₂ <i>t</i> -Bu | CO ₂ Et | 120 | 20 | -- | 22 (4be) + 78 (4ba) | -- | -- |

^aStandard conditions: 5 mol% PdCl₂(PPh₃)₂, 0.5 equiv KI, 1 equiv MA under air in DMF. ^bEquivalents of K_2CO_3 used. ^cNaOAc was used as base. ^dUsing 0.5 equiv of K_2CO_3 , at 120 °C, the conjugate addition product was obtained (42%, see S.I.). ^eTraces of deprotected product were observed by ¹H-NMR.

However, starting from the *N*-ethylcarbamate **5ab** the cascade product **4ab** was isolated in 52% yield under the same reaction conditions (entry 12) and, furthermore, the similar reactions of the carbamate-fumarate substrates **5bb** and **5bd** also afforded the desired alkylidenepaullones in good yields (entries 13-15). It is apparent that reducing the electron density at the palladium-substituted indole C3 position slows down protiodemetallation. As additional benefit, carbamates were expected to exhibit greater solubility thus facilitating the handling of the final product. We also noticed that the indole carbamate underwent partial

deprotection under the thermal conditions required for the Pd-catalyzed cascade reaction (see entries 14 and 15). Since *tert*-butylcarbamates are known to deprotect by thermal fragmentation reaction,²⁶ it was thought that they could directly provide the deprotected indolobenzazepine-6-one. However, this expectation was only partially realized, as the deprotection of the *N*-Boc-*o,o'*-bis(aniline)-ethynes **5ae** and **5be** (obtained from previously described²⁷ **6e**) to **4ae** and **4be** was incomplete after heating to 120 °C (**4ae**, 25%; **4aa**, 29%; **4ae**, 22%; **4ba**, 78%, Table 1, entries 16 and 17). Nevertheless, the

use of *tert*-butylcarbamate **5be** allowed the isolation of **4ba** (a product that could not be obtained from fumarate **5ba**) in useful yield (78%).

The structures of indolobenzazepinones **4ab** and **4bb** were confirmed by X-Ray analysis (see S.I.), which also corroborated the geometry of the exocyclic olefin, as anticipated from the stereospecific *syn*- β -elimination of PdL₂XH from intermediate **III** depicted on Figure 2. As a result, it is confirmed that the products of this highly regio-, stereo- and chemoselective reaction indeed correspond to a 7-*exo* intramolecular Heck-type cyclization process, whereas the indolobenzazepinone products (originating from the alternative 8-*endo* cyclization manifold^{28,29}), which have been observed in other substrates,³⁰ were not detected. Furthermore, the only products that were isolated originated from the manifold where the *N* further removed from the pendant alkenyl chain participated in the starting nucleopalladation step.

Biological evaluation

To explore the antitumor activities of the alkylidenepaullones, we first assessed their effects on cell cycle progression and cell death using the U937 leukaemia cell line (Figure 3). As shown in Figure 3A, the effect on cell cycle of these compounds was not significant relative to the control, the Zn²⁺-dependent histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) used at 5 μ M. However, some compounds were able to induce cell death at the dose of 50 μ M (Figure 3B).




Figure 3. Effects of alkylidenepaullones on cell cycle (A) and apoptosis (B) after treatment of U937 leukemia cells with the indicated compounds at 50 μ M for 30 h. DMSO (0.1%) was used as vehicle control and SAHA (SA) as reference compound at 5 μ M.

As second analysis, we checked by Western blot the activity of the alkylidenepaullones on a recombinant Sirt1 enzyme.²⁰ Using a Sirt1 assay in conditions that detect both activation and inhibition, compounds **4aa** and **4ac** were found to display an apparent activating effect at 50 μ M (compound STAC used as reference³¹ displayed activation in the same settings at the lower dose of 10 μ M). On the other hand, compounds **4ba**, **4bb**, **4bd** and **4ae** displayed a low inhibitory effect under the same conditions (Figure 4A). When compound **4ac** was tested in MCF7 cells for its ability to activate Sirt1 activity by causing deacetylation of p53 on K382 (a target of sirtuins^{32,33}) after 30 h of treatment (Figure 4B), a dose-dependent effect was noted, suggesting that the effective dose to obtain Sirt1 activation, in the cellular settings, is higher.




Figure 4. Sirt1 activity assay. (A) The indicated compounds were tested at 50 μM . DMSO (0.1%) was used as vehicle control. EX527 and STAC at 5 and 10 μM , respectively, were used as reference compounds. (B) Western blot analysis of p53K382 acetylation levels in MCF7 cells upon increasing concentrations of **4ac** for 30 h. DMSO (0.1%) and STAC (50 μM) were used as reference. Signal quantitation was performed using the ImageJ software.

Conclusion

In conclusion, the Pd-catalyzed *N*-cyclization of *o*-alkynylanilines, combined with an intramolecular oxidative Heck reaction in a cascade process, allows the regioselective construction of the core indole and benzazepinone heterocycles of the polycyclic alkylidenepaullones. The scope of this methodology might be broadened with its application to other heterocyclic analogs (X = O, S in Scheme 1). Some of these compounds appear to activate Sirt1 in biochemical assays, and although at present the concentration required for their activity is higher than those of existing compounds, they represent a useful starting point for further additional structural studies aimed to improve their potencies as sirtuin activators.

Acknowledgements

The authors thank the Spanish Ministerio de Economía y Competitividad (MINECO) (FEDER, grant number CTQ2012-37734, SAF201348397-R, and SAF2010-17935, FPI fellowship to J. G. Denis) and Ministero Italiano dell'Istruzione Università e Ricerca (PRIN 2012ZHN9YH).

^aDepartamento de Química Orgánica, Facultad de Química (CINBIO) and Instituto de Investigación Biomédica de Vigo (IBIV), Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo (Spain).
 Fax: +34 986 811940; Tel: +34 986 812316; E-mail: rar@uvigo.es; golera@uvigo.es

^bSeconda Università degli Studi di Napoli, Dipartimento di Biochimica, Biofisica e Patologia generale, Vico L. De Crecchio 7, 80138, Napoli (Italy).

^cDepartamento de Química Orgánica II, Facultad de Ciencia y Tecnología, Universidad del País Vasco, Apartado 644, 48080 Bilbao (Spain).

† Electronic Supplementary Information (ESI) available: ESI contains General Experimental Procedures, copies of the NMR spectra of the new compounds and X-ray diffraction data for **4ab** and **4bb**. See DOI:

Experimental Section

Ethyl (2-Iodophenyl)carbamate **6b**.³⁴ 2-Iodoaniline **6a** (1.2 g, 5.478 mmol), ethylchloroformate (2.37 g, 21.916 mmol) and K_2CO_3 (4.54 g, 32.873 mmol) were stirred in 20 mL of acetone at room temperature for 18 h. The solution was diluted with H_2O . The organic phase was separated, and the solvent was evaporated. The residue was purified by column chromatography (silica gel, 70:30 hexane/EtOAc) to afford 1.57 g (99%) of the titled compound as a white solid. $^1\text{H-NMR}$ (400.16 MHz, CDCl_3) δ 8.06 (d, $J = 8.1$ Hz, 1H), 7.75 (dd, $J = 7.9, 1.2$ Hz, 1H), 7.33 (t, $J = 7.8$ Hz, 1H), 6.94 (s, 1H), 6.80 (t, $J = 7.6$ Hz, 1H), 4.25 (q, $J = 7.1$ Hz, 2H), 1.34 (t, $J = 7.1$ Hz, 3H) ppm. $^{13}\text{C-NMR}$ (100.62 MHz, CDCl_3) δ 153.6, 138.9, 138.6, 129.4, 125.1, 120.4, 88.9, 61.7, 14.6. ppm.

tert-Butyl (2-Iodophenyl)carbamate **6e**.³⁰ A solution of 2-iodoaniline **6a** (500 mg, 2.283 mmol) and $(\text{Boc})_2\text{O}$ (797.2 mg, 3.653 mmol) in THF (4 mL) was refluxed for 4 days. Then H_2O was added and the mixture was extracted with AcOEt (3x) and the combined organic layers were dried (Na_2SO_4) and the solvent was evaporated. The residue was purified by flash chromatography (silica gel, 90:10 hexane/EtOAc) to afford 0.705 g (97%) of **6e** as white crystals. $^1\text{H-NMR}$ (400.16 MHz, CDCl_3) δ 8.05 (d, $J = 8.2$ Hz, 1H), 7.74 (dd, $J = 7.9, 1.4$ Hz, 1H), 7.31 (t, $J = 7.8$ Hz, 1H), 6.82 (s, 1H), 6.76 (ddd, $J = 8.8, 7.6, 1.5$ Hz, 1H), 1.54 (s, 9H) ppm. $^{13}\text{C-NMR}$ (100.62 MHz, CDCl_3) δ 152.7, 138.9, 138.9, 129.3, 124.8, 120.3, 88.9, 81.2, 28.4 ppm.

Ethyl (4-bromo-2-iodophenyl)-carbamate **6d**. Ethyl chloroformate (115 μL , 1.217 mmol) was added to a solution of commercial 4-bromo-2-iodoaniline **6c** (250 mg, 0.839 mmol) in pyridine (1.13 mL) at 0-10 $^\circ\text{C}$ and the mixture was stirred for 3 h. The pyridine was evaporated and the residue was diluted with H_2O and extracted with Et_2O (3x). The

combined organic layers were washed with a 3M aqueous solution of HCl and a saturated aqueous solution of NaHCO₃ and dried (Na₂SO₄) and the solvent was evaporated. The residue was purified by column chromatography (silica gel, 5:5:5 hexane/EtOAc) to afford 282.1 mg (91%) of the title compound as a white solid m.p.: 105-106 °C (CH₂Cl₂); ¹H-NMR (400.16 MHz, CDCl₃) δ 7.97 (d, *J* = 8.6 Hz, 1H, H₆), 7.87 (d, *J* = 2.3 Hz, 1H, H₃), 7.44 (dd, *J* = 8.8, 2.3 Hz, 1H, H₅), 6.91 (s, 1H, NH), 4.24 (q, *J* = 7.0 Hz, 2H, CH₂-CH₃), 1.34 (t, *J* = 7.0 Hz, 3H, CH₂-CH₃) ppm. ¹³C-NMR (100.62 MHz, CDCl₃) δ 153.3, 140.6, 137.9, 132.2, 121.0, 116.3, 88.7, 61.9, 14.6 ppm. MS (EI): *m/z* (%) 370 (M⁺, ⁸¹Br, 37), 368 (M⁺, ⁷⁹Br, 36), 324 (94), 322 (100), 298 (33), 296 (35), 215 (85), 213 (71), 170 (31), 169 (65), 167 (46), 63 (29). HMRS (EI): Calcd. for C₉H₉⁷⁹BrINO₂ 370.8841; found, 370.8845. Calcd. for C₉H₉⁷⁹BrINO₂ 368.8861; found, 368.8865. IR (neat): ν 3293 (w, N-H), 2980 (w, C-H), 2929 (w, C-H), 1730 (s, C=O) cm⁻¹.

N-(2-Ethynylphenyl)-acrylamide **7a**. Acryloyl chloride (79 μL, 0.971 mmol) was added to a solution of 2-ethynylaniline **8** (0.13 g, 0.883 mmol) in CH₂Cl₂ (8.8 mL) and Et₃N (0.14 mL) at 0 °C. After stirring for 30 min at 25 °C, an aqueous saturated solution of NH₄Cl was added and the mixture was extracted with Et₂O (3x). The combined organic layers were dried (Na₂SO₄) and the solvent was evaporated. The residue was purified by column chromatography (silica gel, 90:10 hexane/EtOAc) to afford 144 mg (87%) of the titled compound as a white solid. m.p.: 91-92 °C (CH₂Cl₂). ¹H-NMR (400.16 MHz, CDCl₃): δ 8.46 (d, *J* = 8.4 Hz, 1H, ArH), 8.11 (s, 1H, NH), 7.42 (dd, *J* = 7.7, 1.6 Hz, 1H, ArH), 7.39 – 7.28 (m, 1H, ArH), 7.01 (td, *J* = 7.6, 1.2 Hz, 1H, ArH), 6.40 (dd, *J* = 16.9, 1.4 Hz, 1H, H₂), 6.28 (dd, *J* = 16.9, 10.0 Hz, 1H, H_{3trans}), 5.74 (dd, *J* = 10.0, 1.4 Hz, 1H, H_{3cis}), 3.55 (s, 1H). ¹³C-NMR (100.62 MHz, CDCl₃) δ 163.3, 139.2, 132.1, 131.2, 130.0, 127.8, 123.4, 119.5, 111.0, 84.7, 79.0 ppm. MS (EI): *m/z* (%) 171 (M⁺, 46), 143 (11), 117 (100), 90 (19), 89 (21). HMRS (EI): Calcd. for C₁₁H₉NO 171.0684; found, 171.0689. IR (neat): ν 3379 (s, N-H), 3255 (s, Csp-H), 3209 (s, Csp²-H), 2195 (w, C≡C), 1665 (s, C=O) cm⁻¹.

Ethyl (*E*)-4-(2-Ethynylphenylamino)-4-oxobut-2-enoate **7b**. To a solution of **8** (0.25g, 1.552 mmol) in Et₂O (7.75 mL) was added pyridine (139 μL, 1.707 mmol). After cooling down to -78 °C, a solution of ethyl (*E*)-4-chloro-4-oxobut-2-enoate (0.25 g, 1.552 mmol) in Et₂O (2.35 mL) was added dropwise. The resulting suspension was warmed to 25 °C for 1 h and then partitioned between EtOAc (50 mL) and brine (50 mL). The layers were separated and the aqueous layers was extracted with EtOAc (3 x) and the combined organic layers were washed with a 5% aqueous HCl solution (100 mL) and brine (100 mL) and dried (Na₂SO₄) and the solvent was evaporated. The residue was purified by flash chromatography (silica gel, 90:10 hexane/EtOAc) to afford 0.38 g (99%) of the title compound as white crystals. m.p.: 139 °C (Et₂O). ¹H-NMR (400.16 MHz, CDCl₃) δ 8.51 (d, *J* = 8.4 Hz, 1H, ArH), 8.19 (s, 1H, NH), 7.49 (dd, *J* = 7.8, 1.5 Hz, 1H, ArH), 7.40 (td, *J* = 8.0, 1.6 Hz, 1H, ArH), 7.10 (td, *J* = 7.6, 1.1 Hz, 1H,

ArH), 7.07 (d, *J* = 15.3 Hz, 1H), 6.96 (d, *J* = 15.3 Hz, 1H), 4.29 (q, *J* = 7.1 Hz, 2H, CH₂-CH₃), 3.58 (s, 1H), 1.35 (t, *J* = 7.1 Hz, 3H, CH₂-CH₃) ppm. ¹³C-NMR (100.62 MHz, CDCl₃) δ 165.4, 161.5, 139.0, 136.4, 132.4, 131.9, 130.4, 124.3, 119.7, 111.2, 85.3, 79.0, 61.5, 14.2 ppm. MS (EI): *m/z* (%) 243 (M⁺, 52), 198 (13), 170 (43), 127 (23), 117 (100), 116 (17), 99 (19), 89 (20). HMRS (EI): Calcd. for C₁₄H₁₃NO₃ 243.0895; found, 243.0893. IR (neat): ν 3289 (w, N-H), 3247 (s, ≡C-H), 1712 (s, C=O), 1641 (s, C=O) cm⁻¹.

N-[2-(2-Aminophen-1-ylethynyl)-phenyl]acrylamide **5aa**.

General procedure for the Sonogashira reaction. To a solution of 2-iodoaniline **6a** (0.025 g, 1.141 mmol) in THF (12 mL) were added PdCl₂(PPh₃)₂ (0.016 g, 0.022 mmol), CuI (0.008 g, 0.045 mmol), Et₃N (2.96 mL) and *N*-(2-ethynylphenyl)-acrylamide **7a** (0.293 g, 1.712 mmol), and the reaction mixture was stirred at 25 °C for 4 h. The mixture was poured into H₂O and then extracted with EtOAc (3x). The combined organic layers were dried (Na₂SO₄), and the solvent was evaporated. The residue was purified by column chromatography (silica gel, 80:20 hexane/EtOAc) to afford the title compound (292.5 mg, 98%) as a yellowish-brown solid. m.p.: 94-95 °C (CH₂Cl₂). ¹H-NMR (400.16 MHz, CDCl₃) δ 8.49 (d, *J* = 6.7 Hz, 1H, ArH), 8.23 (s, 1H, NH), 7.49 (d, *J* = 7.7 Hz, 1H, ArH), 7.43 – 7.28 (m, 2H, ArH), 7.19 (t, *J* = 7.8 Hz, 1H, ArH), 7.09 (t, *J* = 7.6 Hz, 1H, ArH), 6.85-6.70 (m, 2H, ArH), 6.44 (dd, *J* = 17.0, 1.6 Hz, 1H, H_{3trans}), 6.31 (dd, *J* = 16.9, 10.1 Hz, 1H, H₂), 5.76 (dd, *J* = 10.2, 1.6 Hz, 1H, H_{3cis}), 4.32 (s, 2H, NH₂) ppm. ¹³C-NMR (100.62 MHz, CDCl₃) δ 163.5, 148.0, 138.5, 132.0, 131.5, 131.4, 130.5, 129.7, 127.9, 123.8, 119.7, 118.3, 114.8, 112.6, 107.1, 93.4, 89.5 ppm. MS (EI): *m/z* (%) 262 (M⁺, 5), 244 (64), 243 (100), 242 (27), 204 (11). HMRS (EI): Calcd. for C₁₇H₁₄N₂O, 262.1106; found, 262.1097. IR (neat): ν 3436 (s, N-H), 3380-3350 (m, N-H), 3293 (w, Csp²-H), 2210 (w, C≡C), 1659 (s, C=O) cm⁻¹.

N-{2-[(*N*-Ethoxycarbonyl-2-aminophenyl)-ethynyl]-phenyl}-acrylamide **5ab**. Following the general procedure for the Sonogashira reaction, the reaction of ethyl (4-bromo-2-iodophenyl)-formiate **6b** (100 mg, 0.343 mmol), *N*-(2-ethynylphenyl)-acrylamide **7a** (88 mg, 0.515 mmol), PdCl₂(PPh₃)₂ (0.005 g, 0.007 mmol), CuI (0.003 g, 0.014 mmol) and Et₃N (0.89 mL) in THF (3.6 mL) afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 114.8 mg (100%) of the titled compound as a white solid. m.p.: 158-159 °C (CH₂Cl₂). ¹H-NMR (400.16 MHz, CDCl₃) δ 8.51 (d, *J* = 8.4 Hz, 1H, ArH), 8.14 (d, *J* = 8.8 Hz, 1H), 8.08 (br, 1H, NH), 7.57 – 7.49 (m, 1H, ArH), 7.48 (ddd, *J* = 7.7, 1.6, 0.5 Hz, 1H, ArH), 7.46 – 7.35 (m, 2H, ArH), 7.30 (br, 1H, NH), 7.13 (td, *J* = 7.6, 1.2 Hz, 1H, ArH), 7.07 (td, *J* = 7.6, 1.1 Hz, 1H, ArH), 6.44 (dd, *J* = 16.9, 1.4 Hz, 1H, H₂), 6.31 (dd, *J* = 16.9, 10.1 Hz, 1H, H_{3A}), 5.78 (dd, *J* = 10.1, 1.4 Hz, 1H, H_{3B}), 4.23 (q, *J* = 7.1 Hz, 2H, CH₂), 1.31 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C-NMR (100.62 MHz, CDCl₃) δ 163.5, 153.3, 139.1, 138.9, 132.1, 132.0, 131.4, 130.5, 130.4, 128.1, 123.9, 123.1, 120.1, 118.8, 111.9, 111.3, 91.6, 90.9, 61.7, 14.6 ppm. MS (EI): *m/z* (%) 334 (M⁺, 4), 288 (27), 287

(21), 260 (14), 259 (12), 246 (24), 244 (71), 243 (100), 242 (23), 234 (76), 206 (24), 205 (30), 204 (16). HMRS (EI): Calcd. for $C_{20}H_{18}N_2O_3$ 334.1337; found, 334.1331. IR (neat): ν 3307 (w, N-H), 2193 (w, C \equiv C), 1705 (s, C=O), 1667 (s, C=O) cm^{-1} .

N-[2-((2-Amino-5-bromophenyl)-ethynyl)-phenyl]-acrylamide **5ac**. Following the general procedure for the Sonogashira reaction, the reaction of 4-bromo-2-iodoaniline **6c** (650 mg, 2.182 mmol), *N*-(2-ethynylphenyl)-acrylamide **7a** (560 mg, 2.273 mmol), $PdCl_2(PPh_3)_2$ (0.031 g, 0.044 mmol), CuI (0.017 g, 0.087 mmol) and Et_3N (5.7 mL) in DMF (23 mL) afforded, after purification by column chromatography (silica gel, 90:10 hexane/EtOAc), 744.4 mg (100%) of the titled compound as a white solid. m.p.: 133-134 °C (CH_2Cl_2). 1H -NMR (400.16 MHz, $CDCl_3$) δ 8.50 (d, J = 8.3 Hz, 1H, ArH), 8.08 (s, 1H, NH), 7.50 (ddd, J = 7.7, 1.6, 0.5 Hz, 1H, ArH), 7.47 (d, J = 2.3 Hz, 1H, ArH), 7.40 (ddd, J = 8.6, 7.5, 1.6 Hz, 1H, ArH), 7.30 – 7.27 (m, 1H, ArH), 7.11 (td, J = 7.6, 1.2 Hz, 1H, ArH), 6.66 (d, J = 8.7 Hz, 1H, ArH), 6.45 (dd, J = 16.9, 1.2 Hz, 1H, H_2), 6.31 (dd, J = 16.9, 10.1 Hz, 1H, H_{3A}), 5.81 (dd, J = 10.2, 1.2 Hz, 1H, H_{3B}), 4.30 (s, 2H, NH_2) ppm. ^{13}C -NMR (100.62 MHz, $CDCl_3$) δ 164.0, 147.5, 139.0, 134.4, 133.5, 132.1, 131.6, 130.5, 128.5, 124.2, 120.2, 116.5, 112.4, 109.5, 109.2, 91.9, 90.7 ppm. MS (EI): m/z (%) 342 (M^+ , ^{81}Br , 20), 340 (M^+ , ^{79}Br , 23), 325 (23), 324 (61), 323 (46), 322 (62), 321 (31), 243 (61), 242 (100), 206 (54), 205 (25). HMRS (EI): Calcd. for $C_{17}H_{13}^{81}BrN_2O$, 342.0191; found, 342.0194. Calcd. for $C_{17}H_{13}^{79}BrN_2O$, 340.0211; found, 340.0212. IR (neat): ν 3449 (w, N-H), 3256 (w, N-H), 3274 (w, N-H), 1654 (s, C=O) cm^{-1} .

N-{2-[(*N*-*tert*-Butoxycarbonyl-2-aminophenyl)-ethynyl]-phenyl}-acrylamide **5ae**. Following the general procedure for the Sonogashira reaction, the reaction of *tert*-butyl 2-iodophenyl formate **6e** (60 mg, 0.188 mmol), *N*-(2-ethynylphenyl)-acrylamide **7a** (39 mg, 0.225 mmol), $PdCl_2(PPh_3)_2$ (0.003 g, 0.004 mmol), CuI (0.001 g, 0.07 mmol) and Et_3N (0.49 mL) in THF (2 mL) afforded, after purification by column chromatography (silica gel, 70:30 hexane/EtOAc), 62.4 mg (92%) of the titled compound as a white solid. m.p.: 135-136 °C ($CDCl_3$). 1H -NMR (400.16 MHz, $CDCl_3$) δ 8.53 (d, J = 8.3 Hz, 1H, ArH), 8.16 (d, J = 8.4 Hz, 1H, ArH), 8.07 (s, 1H, NH), 7.54 (dd, J = 7.7, 1.4 Hz, 1H, ArH), 7.47 (dd, J = 7.7, 1.3 Hz, 1H, ArH), 7.45 – 7.36 (m, 2H, ArH), 7.18 (s, 1H, NH), 7.14 (td, J = 7.6, 1.1 Hz, 1H, ArH), 7.05 (td, J = 7.6, 1.1 Hz, 1H, ArH), 6.45 (dd, J = 16.9, 1.2 Hz, 1H, H_{3A}), 6.31 (dd, J = 16.9, 10.2 Hz, 1H, H_{2B}), 5.80 (dd, J = 10.2, 1.2 Hz, 1H, H_{3B}), 1.52 (s, 9H, $C(CH_3)_3$) ppm. ^{13}C -NMR (100.62 MHz, $CDCl_3$) δ 163.6 (s), 152.6 (s), 139.7 (s), 139.0 (s), 132.2 (d), 132.1 (d), 131.6 (d), 130.7 (d), 130.5 (d), 128.4 (t), 124.1 (d), 122.9 (d), 120.1 (d), 118.7 (d), 111.9 (s), 111.0 (s), 92.0 (s), 90.8 (s), 81.4 (s), 28.5 (q) ppm. MS (ESI $^+$): m/z (%) 385 [($M+Na^+$)], 363 [($M+H^+$)]. HMRS (ESI $^+$): Calcd. for $C_{22}H_{23}N_2O_3$ 363.17032; found, 363.17033. IR (NaCl): ν 3400 (w, N-H), 3295 (w, N-H), 2978 (w, C-H), 1732 (s, C=O), 1688 (s, C=O) cm^{-1} .

Ethyl (*E*)-4-[(2-(2-Aminophenylethynyl)-phenyl)amino]-4-

oxobut-2-enoate **5ba**. Following the general procedure for the Sonogashira reaction, the reaction of 2-iodoaniline **6c** (22 mg, 0.101 mmol), ethyl (*E*)-4-[(2-ethynylphenyl)-amino]-4-oxobut-2-enoate **7b** (37 mg, 0.152 mmol), $PdCl_2(PPh_3)_2$ (0.001 g, 0.002 mmol), CuI (0.001 g, 0.004 mmol) and Et_3N (0.26 mL) in DMF (1.06 mL) at 80 °C afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 25.8 mg (76%) of the titled compound as a white solid. m.p.: 176-179 °C (CH_2Cl_2). 1H -NMR (400.16 MHz, $CDCl_3$) δ 8.50 (d, J = 8.4 Hz, 1H, ArH), 8.41 (s, 1H, NH), 7.51 (dd, J = 7.7, 1.5 Hz, 1H, ArH), 7.43 – 7.33 (m, 2H, ArH), 7.20 (td, J = 7.6, 1.2 Hz, 1H, ArH), 7.18 – 7.07 (m, 2H, ArH + Csp^2 -H), 6.96 (d, J = 15.3 Hz, 1H, Csp^2 -H), 6.82 – 6.73 (m, 2H, ArH), 4.27 (q, J = 7.2 Hz, 2H, CH_2), 1.33 (t, J = 7.1 Hz, 3H, CH_3) ppm. ^{13}C -NMR (100.62 MHz, $CDCl_3$) δ 165.4, 161.6, 148.0, 138.0, 136.5, 132.1, 131.8, 131.7, 130.6, 129.8, 124.4, 120.0, 118.5, 115.0, 112.9, 107.2, 93.9, 89.3, 61.4, 14.2 ppm. MS (EI): m/z (%) 334 (M^+ , 3), 317 (10), 316 (64), 288 (11), 244 (12), 243 (100), 242 (36). HMRS (EI): Calcd. for $C_{20}H_{18}N_2O_3$, 334.1317; found, 334.1318. IR (neat): ν 3482 (w, N-H), 3385 (w, N-H), 3295 (w, N-H), 2204 (w, C=C), 1705 (s, C=O), 1666 (s, C=O) cm^{-1} .

Ethyl (*E*)-4-((2-(2-Ethoxycarbonylamino-phenyl)-ethynyl)-phenyl)-amino)-4-oxobut-2-enoate **5bb**. Following the general procedure for the Sonogashira reaction, the reaction of 2-iodophenyl-formate **6b** (500 mg, 1.718 mmol), ethyl (*E*)-4-(2-ethynylphenylamino)-4-oxobut-2-enoate **7b** (627 mg, 2.576 mmol), $PdCl_2(PPh_3)_2$ (0.024 g, 0.034 mmol), CuI (0.013 g, 0.069 mmol) and Et_3N (4.46 mL) in DMF (18 mL) at 60 °C afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 641.9 mg (92%) of the titled compound as a white solid. m.p.: 168-169 °C (CH_2Cl_2). 1H -NMR (400.16 MHz, $CDCl_3$) δ 8.52 (d, J = 8.4 Hz, 1H, ArH), 8.24 (s, 1H, NH), 8.12 (d, J = 8.4 Hz, 1H, ArH), 7.56 (dd, J = 7.8, 1.5 Hz, 1H, ArH), 7.51 (dd, J = 7.8, 1.6 Hz, 1H, ArH), 7.48 – 7.35 (m, 2H, ArH), 7.18 (td, J = 7.6, 1.1 Hz, 1H, ArH), 7.13 – 7.07 (m, 2H, ArH + Csp^2 -H), 6.97 (d, J = 15.1 Hz, 1H, Csp^2 -H), 4.35-4.15 (m, 4H, $2 \times CH_2$), 1.39 – 1.26 (m, 6H, $2 \times CH_3$) ppm. ^{13}C -NMR (100.62 MHz, $CDCl_3$) δ 165.3, 161.8, 153.3, 139.0, 138.2, 136.3, 132.2, 132.1, 131.8, 130.4, 130.1, 124.6, 123.1, 120.6, 118.9, 112.7, 111.5, 91.8, 90.5, 61.6, 61.3, 14.5, 14.1 ppm. MS (EI): m/z (%) 406 (M^+ , 3), 360 (23), 318 (57), 316 (50), 288 (23), 287 (100), 259 (29), 243 (87), 242 (38), 234 (61), 206 (38), 205 (47). HMRS (EI): Calcd. for $C_{23}H_{22}N_2O_5$, 406.1529; found, 406.1534. IR (neat): ν 3289 (w, N-H), 2978 (w, C-H), 1706 (s, C=O), 1672 (s, C=O) cm^{-1} .

Ethyl (*E*)-4-((2-(5-Bromo-2-ethoxycarbonylamino-phenyl)-ethynyl)-phenyl)-amino)-4-oxobut-2-enoate **5bd**. Following the general procedure for the Sonogashira reaction, the reaction of ethyl (4-bromo-2-iodophenyl)-formate **6b** (100 mg, 0.265 mmol), ethyl (*E*)-4-(2-ethynylphenylamino)-4-oxobut-2-enoate **7b** (97 mg, 0.398 mmol), $PdCl_2(PPh_3)_2$ (0.004 g, 0.005 mmol), CuI (0.002 g, 0.011 mmol) and Et_3N (0.69 mL) in DMF (2.8 mL) at 60 °C afforded, after purification by column chromatography (silica gel, 90:10 hexane/EtOAc), 117.6 mg (90%) of the titled compound as a

white solid. m.p.: 215-216 °C (CH₂Cl₂). ¹H-NMR (400.16 MHz, DMSO-d₆) δ 10.23 (s, 1H, NH), 9.10 (s, 1H, NH), 7.91 (d, *J* = 8.3 Hz, 1H, ArH), 7.77 (d, *J* = 2.4 Hz, 1H, ArH), 7.70 (d, *J* = 8.9 Hz, 1H, ArH), 7.63 (dd, *J* = 7.8, 1.6 Hz, 1H, ArH), 7.58 (dd, *J* = 8.8, 2.4 Hz, 1H, ArH), 7.50 – 7.38 (m, 2H, ArH + Csp²-H), 7.25 (t, *J* = 7.3 Hz, 1H, ArH), 6.78 (d, *J* = 15.4 Hz, 1H, Csp²-H), 4.20 (q, *J* = 7.1 Hz, 2H, CH₂), 4.10 (q, *J* = 7.1 Hz, 2H, CH₂), 1.24 (t, *J* = 7.1 Hz, 3H, CH₃), 1.17 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C-NMR (100.62 MHz, DMSO-d₆) δ 164.9, 161.8, 153.6, 138.3, 138.1, 137.2, 134.5, 132.8, 132.3, 130.2, 129.7, 125.2, 123.7, 123.3, 116.6, 115.2, 115.0, 92.0, 89.9, 60.9, 60.8, 14.4, 14.0 ppm. MS (ESI⁺): *m/z* (%) 509 (M+Na⁺, ⁸¹Br), 507 (M+Na⁺, ⁷⁹Br), 487 (M+H⁺, ⁸¹Br), 485 (M+H⁺, ⁷⁹Br), 340 (6), 318 (8), 290 (4), 262 (3). HMRS (ESI⁺): Calc. for C₂₃H₂₂⁷⁹BrN₂O₅ ([M+H]⁺) 485.07066; found, 485.07086. IR (neat): ν 3293 (m, N-H), 2981 (w, C-H), 1701 (m, C=O), 1671 (s, C=O) cm⁻¹.

Ethyl (*E*)-4-((2-((2-*tert*-Butoxycarbonylamino-phenyl)-ethynyl)-phenyl)-amino)-4-oxobut-2-enoate **5b**. Following the general procedure for the Sonogashira reaction, the reaction of *tert*-butyl 2-iodophenyl formate **6e** (76 mg, 0.238 mmol), ethyl (*E*)-4-(2-ethynylphenylamino)-4-oxobut-2-enoate **7b** (69 mg, 0.286 mmol), PdCl₂(PPh₃)₂ (0.003 g, 0.005 mmol), CuI (0.002 g, 0.009 mmol) and Et₃N (0.62 mL) in DMF (2.5 mL) at 80 °C afforded, after purification by column chromatography (silica gel, 85:15 hexane/EtOAc), 102.1 mg (99%) of the titled compound as white solid. m.p.: 127-128 °C (CDCl₃). ¹H-NMR (400.16 MHz, CDCl₃) δ 8.52 (d, *J* = 8.3 Hz, 1H, ArH), 8.21 (s, 1H, NH), 8.15 (d, *J* = 8.4 Hz, 1H, ArH), 7.56 (dd, *J* = 7.7, 1.2 Hz, 1H, ArH), 7.49 (td, *J* = 7.9, 1.6 Hz, 1H, ArH), 7.50-7.38 (m, 2H, ArH), 7.22 – 7.14 (m, 2H, ArH+NH), 7.12 – 7.02 (m, 2H, ArH + Csp²-H), 6.97 (d, *J* = 15.3 Hz, 1H, Csp²-H), 4.27 (q, *J* = 7.1 Hz, 2H, CH₂), 1.51 (s, 9H, C(CH₃)₃), 1.32 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C-NMR (100.62 MHz, CDCl₃) δ 165.3, 161.7, 152.4, 139.7, 138.3, 136.3, 132.2, 132.1, 132.0, 130.5, 130.2, 124.6, 122.7, 120.5, 118.6, 112.7, 110.9, 92.2, 90.4, 81.2, 61.4, 27.3 (3x), 14.2 ppm. MS (ESI⁺): *m/z* (%) 457 (M+Na⁺), 435 (M+H⁺). HMRS (ESI): Calc. for C₂₅H₂₇N₂O₅ ([M+H]⁺) 435.9145; found, 435.19132. IR (NaCl): ν 3207 (w, N-H), 3267 (w, N-H), 2978 (w, C-H), 1734 (s, C=O), 1666(s, C=O) cm⁻¹.

7-Methylene-6-oxo-6,7-dihydrobenzo[*b*]azepino[4,5-*b*]indole **9aa** and *N*-(2-indol-2-yl-phenyl)-acrylamide **4aa**. General procedure for the *N*-cyclization-Heck reaction. To a solution of **5aa** (32 mg, 1.122 mmol) in DMF (3 mL) were added PdCl₂(PPh₃)₂ (4 mg, 0.006 mmol), KI (10 mg, 0.061 mmol), MA (12 mg, 0.122 mmol) and the reaction was heated at 100 °C for 3 hours, in air atmosphere. The reaction was cooled down to 25 °C and a saturated aqueous solution of NaCl (25 mL) was added. The mixture was extracted with EtOAc (3 x), the combined organic layers were washed with water (15 mL) and dried (Na₂SO₄), and the solvent was evaporated. The residue was purified by flash chromatography to afford 17.4 mg (37%) of **9aa** and 12.3 mg (40%) of **4aa**. Data for **4aa**: m.p.: 180 °C (dec.) (CH₂Cl₂). ¹H-NMR (400.16 MHz, DMSO-d₆) δ 10.37 (s, 1H, NH), 7.79 (dd, *J* = 7.9, 1.5

Hz, 1H, ArH), 7.71 (d, *J* = 8.0 Hz, 1H, ArH), 7.48 (d, *J* = 8.0 Hz, 1H, ArH), 7.36 (ddd, *J* = 8.3, 7.1, 1.5 Hz, 1H, ArH), 7.30 (dd, *J* = 8.2, 1.4 Hz, 1H, ArH), 7.24 (ddd, *J* = 8.2, 6.9, 1.3 Hz, 2H, ArH), 7.12 (ddd, *J* = 8.1, 7.1, 1.1 Hz, 1H, ArH), 6.12 (d, *J* = 1.7 Hz, 1H, Csp²-H), 5.74 (d, *J* = 1.7 Hz, 1H, Csp²-H) ppm. ¹³C-NMR (100.62 MHz, DMSO-d₆) δ 170.6, 137.7, 135.7, 134.7, 132.4, 128.6, 126.6, 126.0, 123.6, 123.0, 121.6, 121.1, 120.5, 120.0, 118.6, 111.6, 110.7 ppm. HMRS (ESI⁺): Calcd. for C₁₇H₁₃N₂O ([M+1]⁺) 261.10224; found, 261.10233. IR (neat): ν 3253 (s, C=H), 1644 (s, C=O) cm⁻¹.

Data for **9aa**: ¹H-NMR (400 MHz, CDCl₃) δ 8.70 (s, 1H, NH), 8.43 (d, *J* = 8.6 Hz, 1H, ArH), 8.06 (s, 1H, NH), 7.68 (dt, *J* = 7.9, 1.1 Hz, 1H, ArH), 7.49 – 7.40 (m, 2H, ArH), 7.36 (ddd, *J* = 8.7, 7.5, 1.6 Hz, 1H, ArH), 7.27 (ddd, *J* = 8.2, 6.0, 1.3 Hz, 1H, ArH), 7.22 – 7.16 (m, 2H, ArH), 6.66 (dd, *J* = 2.1, 1.0 Hz, 1H, ArH), 6.34 (dd, *J* = 16.9, 1.2 Hz, 1H, H₂), 6.11 (dd, *J* = 16.9, 10.3 Hz, 1H, H_{3trans}), 5.70 (dd, *J* = 10.2, 1.1 Hz, 1H, H_{3cis}) ppm. ¹³C-NMR (100.62 MHz, CDCl₃) δ 163.9, 136.8, 135.2, 134.0, 131.3, 129.4, 129.3, 128.8, 128.0, 124.7, 123.5, 122.9, 121.6, 120.8, 120.6, 111.3, 102.6 ppm. MS (EI): *m/z* (%) 262 (M⁺, 3), 244 (83), 243 (100), 242 (34). HMRS (EI): Calcd. for C₁₇H₁₄N₂O 262.1106; found, 262.1094. IR (neat): ν 3336 (m, N-H), 3209 (m, N-H), 2975 (w, C-H), 2927 (w, C-H), 1649 (s, C=O) cm⁻¹.

Ethyl 7-Methylene-6-oxo-6,7-dihydrobenzo[2,3]azepino[4,5-*b*]indole-12(5*H*)-carboxylate **4ab**. Following the general procedure for *N*-cyclization-Heck reaction, the reaction of acrylamide **5ab** (25 mg, 0.075 mmol), PdCl₂(PPh₃)₂ (0.003 g, 0.004 mmol), KI (0.006 g, 0.037 mmol), MA (7 mg, 0.075 mmol) in DMF (1.8 mL) at 100 °C afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 13.0 mg (52%) of the titled compound as a white solid. m.p.: 205-208 °C (CH₂Cl₂). ¹H-NMR (400 MHz, DMSO-d₆) δ 10.37 (s, 1H, NH), 8.12 (d, *J* = 8.4 Hz, 1H, ArH), 7.72 (d, *J* = 7.8 Hz, 1H, ArH), 7.49 – 7.43 (m, 1H), 7.40 (d, *J* = 7.9 Hz, 1H, ArH), 7.39 – 7.33 (m, 2H), 7.28 (d, *J* = 7.3 Hz, 1H), 7.20 – 7.15 (m, 1H), 6.20 (d, *J* = 1.1 Hz, 1H, Csp²-H), 5.87 (d, *J* = 1.1 Hz, 1H, Csp²-H), 4.31 (q, *J* = 7.1 Hz, 2H, CH₂), 1.13 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C-NMR (100.62 MHz, DMSO-d₆) δ 172.2, 151.0, 137.7, 134.6, 134.0, 132.5, 129.8, 128.5, 126.6, 126.0, 124.5, 123.8, 123.1, 122.5, 122.2, 120.9, 119.0, 114.7, 63.7, 13.6 ppm. HMRS (ESI⁺): Calcd. for C₂₀H₁₇N₂O₃ ([M+H]⁺) 333.12337; found, 333.12402. IR (neat): ν 3192 (w, N-H), 3068 (w, N-H), 2970 (w, C-H), 2923 (w, C-H), 1737 (s, C=O), 1660 (s, C=O) cm⁻¹. X-Ray: See Supporting Information.

9-Bromo-7-Methylene-6-oxo-6,7-dihydrobenzo[*b*]azepino[4,5-*b*]indole **9ac** and *N*-(2-(5-bromoindol-2-yl)-phenyl)-acrylamide **4ac**. Following the general procedure for *N*-cyclization-Heck reaction, the reaction of acrylamide **5ac** (32 mg, 0.094 mmol), PdCl₂(PPh₃)₂ (0.003 g, 0.005 mmol), KI (0.008 g, 0.047 mmol), MA (9 mg, 0.094 mmol) in DMF (2.3 mL) at 80 °C afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 15.8 mg (50%) of **9ac** and 15.9 mg (50%) of **4ac** as a white solid.

Data for **4ac**: m.p.: 200 °C (dec) (CH₂Cl₂). ¹H-NMR (400.16 MHz, DMSO-d₆) δ 10.40 (s, 1H, NH), 7.80 (d, *J* = 2.0 Hz, 1H, ArH), 7.77 (d, *J* = 8.0 Hz, 1H, ArH), 7.44 (dd, *J* = 8.6, 1.2 Hz, 1H, ArH), 7.41 – 7.22 (m, 4H, ArH), 6.12 (s, 1H, Csp²-H), 5.75 (s, 1H, Csp²-H) ppm. ¹³C-NMR (100.62 MHz, DMSO-d₆) δ 170.5, 136.4, 135.1, 135.0, 133.8, 129.2, 127.8, 126.9, 125., 123.7, 121.8, 121.4, 120.7, 120.7, 113.7, 112.6, 110.1 ppm. HMRS (ESI⁺): Calc. for C₁₇H₁₂⁷⁹BrN₂O ([M+H]⁺) 339.01275; found, 339.01264. IR (neat): ν 3256 (w, C-H), 3036 (w, C-H), 1648 (s, C=O) cm⁻¹.

Data for **9ac**: m.p.: 94-96 °C (CH₂Cl₂). ¹H-NMR (400.16 MHz, DMSO-d₆) δ 9.96 (s, 1H, NH), 7.93 (d, *J* = 1.9 Hz, 1H, ArH), 7.87 (dd, *J* = 7.8, 1.3 Hz, 1H, ArH), 7.63 (d, *J* = 8.1 Hz, 1H, ArH), 7.59 (d, *J* = 8.7 Hz, 1H, ArH), 7.46 (m, 2H, ArH), 7.38 (td, *J* = 7.7, 1.1 Hz, 1H, ArH), 6.53 (dd, *J* = 16.9, 10.2 Hz, 1H, H₂), 6.26 (dd, *J* = 17.1, 1.9 Hz, 1H, H_{3trans}), 5.80 (dd, *J* = 10.2, 1.6 Hz, 1H, H_{3cis}) ppm. ¹³C NMR (101 MHz, DMSO-d₆) δ 163.7, 154.3, 152.7, 151.8, 134.6, 131.6, 131.0, 129.5, 128.1, 127.2, 127.2, 127.1, 126.1, 123.7, 115.4, 113.1, 104.5 ppm. MS (ESI⁺): *m/z* (%) 343 ([M+H]⁺, ⁸¹Br), 341 ([M+H]⁺, ⁷⁹Br). HMRS (ESI⁺): Calcd. for C₁₇H₁₄⁷⁹BrN₂O ([M+H]⁺) 341.02840; found, 341.02751. IR (neat): ν 3364 (s, N-H), 3265 (w, N-H), 1669 (s, C=O) cm⁻¹.

Ethyl (*E*)-4-(2-(1*H*-indol-2-yl)-phenylamino)-4-oxobut-2-enoate **9ba**. Following the general procedure for *N*-cyclization-Heck reaction, the reaction of compound **5ba** (65 mg, 0.194 mmol), PdCl₂(PPh₃)₂ (0.007 g, 0.010 mmol), KI (0.016 g, 0.097 mmol), MA (19 mg, 0.194 mmol) in DMF (4.75 mL) at 100 °C afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 45.1 mg (70%) of the titled compound as a white solid. m.p.: 131 °C (CH₂Cl₂). ¹H-NMR (400.16 MHz, CDCl₃) δ 8.59 (s, 1H, NH), 8.46 (d, *J* = 8.3 Hz, 1H, ArH), 8.27 (s, 1H, NH), 7.70 (d, *J* = 7.9 Hz, 1H, ArH), 7.56-7.40 (m, 2H, ArH), 7.38 (t, *J* = 8.1 Hz, 1H, ArH), 7.28 (t, *J* = 8.1 Hz, 1H, ArH), 7.32-7.18 (m, 2H, ArH), 6.87 (app s, 2H, 2x Csp²-H), 6.67 (d, *J* = 0.9 Hz, 1H, ArH), 4.23 (q, *J* = 7.1 Hz, 2H, CH₂), 1.30 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C-NMR (100.62 MHz, CDCl₃) δ 165.3, 161.9, 136.8, 136.2, 134.8, 133.6, 131.9, 129.5, 129.3, 128.8, 125.2, 123.6, 123.1, 121.6, 121.0, 120.8, 111.3, 102.8, 61.4, 14.2 ppm. MS (EI): *m/z* (%) 334 (M⁺, 12), 317 (25), 316 (94), 288 (38), 244 (23), 243 (100), 242 (79). HMRS (EI): Calcd. for C₂₀H₁₈N₂O₃ 334.1317; found, 334.1325. IR (neat): ν 3216 (br, N-H), 3058 (w, C-H), 2925 (w, C-H), 1706 (s, C=O), 1670 (s, C=O) cm⁻¹.

Ethyl (*Z*)-7-(2-Ethoxy-2-oxoethylene)-6-oxo-6,7-dihydrobenzo[2,3]azepino[4,5-*b*]indole-12(5*H*)-carboxylate **4bb** and (*Z*)-7-(2-ethoxy-2-oxoethylene)-6-oxo-6,7-dihydrobenzo[*b*]azepino[4,5-*b*]indole **4ba**. Following the general procedure for *N*-cyclization-Heck reaction, the reaction of compound **5bb** (35 mg, 0.861 mmol), PdCl₂(PPh₃)₂ (0.030 g, 0.043 mmol), KI (0.071 g, 0.430 mmol), MA (84 mg, 0.861 mmol) in DMF (21 mL) at 110 °C afforded, after purification by column chromatography (silica gel, 70:30 hexane/EtOAc), 23.9 mg (80%) of **4bb** and 4.9 mg (20%) of **4ba** as a white solid.

Data for **4bb**. m.p.: 200 °C (dec) (CH₂Cl₂). ¹H-NMR (400

MHz, CDCl₃) δ 8.83 (s, 1H, NH), 8.20 (d, *J* = 8.3 Hz, 1H, ArH), 7.79 (dd, *J* = 7.7, 1.2 Hz, 1H, ArH), 7.45 (ddd, *J* = 8.5, 7.3, 1.3 Hz, 1H, ArH), 7.41 – 7.31 (m, 3H, ArH), 7.28 (d, *J* = 7.9 Hz, 1H, ArH), 7.20 (td, *J* = 7.5, 1.4 Hz, 1H, ArH), 6.31 (s, 1H, Csp²-H), 4.35 (q, *J* = 7.2 Hz, 2H, CH₂), 4.25 (q, *J* = 7.1 Hz, 2H, CH₂), 1.31 (t, *J* = 7.1 Hz, 3H, CH₃), 1.21 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C-NMR (100.62 MHz, CDCl₃) δ 168.7, 164.7, 151.5, 139.0, 138.6, 133.9, 132.9 (2x), 129.9, 128.7, 126.4, 125.0 (2x), 124.1, 123.9, 122.8, 121.7, 119.2, 115.4, 63.8, 61.1, 13.9, 13.8 ppm. HMRS (ESI⁺): Calc. for C₂₃H₂₁N₂O₅ ([M+H]⁺) 405.14450; found, 405.14453. FTIR (neat): ν 3290 (w, N-H), 2922 (w, C-H), 1731 (s, C=O), 1712 (s, C=O) cm⁻¹. X-Ray: See Supporting Information.

Data for **4ba**. m.p.: 230-232 °C (CH₂Cl₂). ¹H-NMR (400.16 MHz, DMSO-d₆) δ 10.75 (s, 1H, NH), 7.78 (d, *J* = 7.9 Hz, 1H, ArH), 7.66 (d, *J* = 7.9 Hz, 1H, ArH), 7.50 (d, *J* = 8.1 Hz, 1H, ArH), 7.40 (t, *J* = 7.1 Hz, 1H, ArH), 7.34 – 7.22 (m, 3H, ArH), 7.16 (t, *J* = 7.5 Hz, 1H, ArH), 6.21 (s, 1H, Csp²-H), 4.13 (q, *J* = 7.1 Hz, 2H, CH₂), 1.23 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C-NMR (100.62 MHz, DMSO-d₆) δ 166.1, 165.6, 139.8, 137.8, 134.2, 133.7, 128.9, 127.1, 125., 124.0, 123.4 (2x), 122.1, 121.3, 120.6, 118.2, 112.0, 110.4, 60.2, 13.9 ppm. HMRS (ESI⁺): Calcd. for C₂₀H₁₇N₂O₃ ([M+H]⁺) 333.12337; found, 333.12361. IR (neat): ν 3333 (w, N-H), 3038 (w, C-H), 2921 (w, C-H), 1710 (s, C=O), 1618 (s, C=O) cm⁻¹.

(*Z*)-Ethyl 9-Bromo-7-(2-ethoxy-2-oxoethylene)-6-oxo-6,7-dihydrobenzo[2,3]azepino[4,5-*b*]indole-12(5*H*)-carboxylate **4bd**. Following the general procedure for *N*-cyclization-Heck reaction, the reaction of compound **5bd** (22 mg, 0.045 mmol), PdCl₂(PPh₃)₂ (2 mg, 0.002 mmol), KI (4 mg, 0.022 mmol), MA (4 mg, 0.045 mmol) in DMF (1.2 mL) at 120 °C afforded, after purification by column chromatography (silica gel, 80:20 hexane/EtOAc), 13.0 mg (60%) of the titled compound as a white solid. m.p.: 250 °C (CH₂Cl₂). ¹H-NMR (400.16 MHz, DMSO-d₆) δ 10.79 (s, 1H, NH), 8.10 (d, *J* = 8.8 Hz, 1H, ArH), 7.77 (d, *J* = 2.1 Hz, 1H, ArH), 7.65 (dt, *J* = 8.9, 1.7 Hz, 1H, ArH), 7.50 (dd, *J* = 8.0, 1.5 Hz, 1H, ArH), 7.42 (t, *J* = 7.6 Hz, 1H, ArH), 7.30 (d, *J* = 8.1 Hz, 1H, ArH), 7.22 (t, *J* = 7.6 Hz, 1H, ArH), 6.52 (s, 1H, Csp²-H), 4.42 – 4.24 (br, 2H, CH₂), 4.15 (q, *J* = 7.0 Hz, 2H, CH₂), 1.25 (t, *J* = 7.1 Hz, 3H, CH₃), 1.14 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C-NMR (100.62 MHz, DMSO-d₆) δ 167.8, 164.8, 150.4, 137.8, 136.6, 134.7, 133.8, 130.3, 129.1, 128.8, 127.4, 125.4, 123.5, 122.7, 122.5, 121.0, 119.2, 117.1, 116.5, 64.2, 60.6, 13.8, 13.6 ppm. HMRS (ESI⁺): Calc. mass for C₂₃H₂₀⁷⁹BrN₂O₅ ([M+H]⁺) 483.05501; found, 483.05485. IR (neat): ν 3293 (w, N-H), 3070 (w, C-H), 2978 (w, C-H), 1731 (s, C=O), 1711 (s, C=O), 1665 (s, C=O) cm⁻¹.

tert-Butyl 7-Methylene-6-oxo-6,7-dihydrobenzo[2,3]azepino[4,5-*b*]indole-12(5*H*)-carboxylate **4ae** and *N*-(2-indol-2-yl-phenyl)-acrylamide **4aa**. Following the general procedure for *N*-cyclization-Heck reaction, the reaction of compound **5ae** (20 mg, 0.055 mmol), PdCl₂(PPh₃)₂ (0.002 g, 0.003 mmol), KI (0.005 g, 0.028 mmol), MA (5 mg, 0.055 mmol) in DMF (1.4 mL) at 110 °C afforded, after purification by column chromatography (silica gel, 70:30 hexane/EtOAc), 4.3 mg (22%) of **4ae** and 11.1 mg (78%) of

4aa as a white solid.

Data for **4ae**. m.p.: > 150 °C (dec.) (CDCl₃). ¹H-NMR (400 MHz, CDCl₃) δ 8.22 (s, 1H, NH), 8.20 (d, *J* = 8.4 Hz, 1H, ArH), 7.75 (d, *J* = 7.8 Hz, 1H, ArH), 7.46 – 7.38 (m, 2H, ArH), 7.32 (dd, *J* = 11.2, 4.6 Hz, 2H, ArH), 7.21 (td, *J* = 7.8, 1.1 Hz, 1H, ArH), 7.13 (d, *J* = 8.0 Hz, 1H, ArH), 6.39 (d, *J* = 1.0 Hz, 1H, Csp²-H), 5.93 (s, 1H, Csp²-H), 1.41 (s, *J* = 12.8 Hz, 9H, CH₃) ppm. ¹³C-NMR (100 MHz, CDCl₃) δ 174.7 (s), 150.8 (s), 139.4 (s), 135.0 (s), 133.8 (s), 133.3 (s), 130.8 (d), 128.9 (d), 127.7 (s), 126.4 (d), 125.6 (t), 124.1 (s), 124.0 (d), 124.0 (d), 122.2 (d), 121.8 (s), 119.5 (d), 115.3 (d), 84.6 (s), 27.4 (q) ppm. MS (ESI): *m/z* (%) 361 (M⁺), 331, 305, 287, 233. HMRS (ESI): Calcd. for C₂₂H₂₁N₂O₃ 361.15467; found, 361.15474. FTIR (NaCl): ν 3403 (w, N-H), 3311 (w, C-H), 2980 (w, C-H), 1726 (s, C=O), 1689 (s, C=O) cm⁻¹.

Ethyl (Z)-7-(2-*tert*-butoxy-2-oxoethylene)-6-oxo-6,7-dihydrobenzo[2,3]azepino[4,5-*b*]indole-12(5*H*)-carboxylate **4be** and (Z)-7-(2-ethoxy-2-oxoethylene)-6-oxo-6,7-dihydrobenzo[*b*]azepino[4,5-*b*]indole **4ba**. Following the general procedure for *N*-cyclization-Heck reaction, the reaction of compound **5be** (34 mg, 0.078 mmol), PdCl₂(PPh₃)₂ (3 mg, 0.004 mmol), KI (6 mg, 0.039 mmol), MA (8 mg, 0.078 mmol) in DMF (2 mL) at 120 °C afforded, after purification by column chromatography (silica gel, 60:40 hexane/EtOAc), 7.44 mg (22%) of **4be** and 20.3 mg (78%) of **4ba**.

Data for **4be**. m.p.: > 250 °C (dec.) (CDCl₃). ¹H-NMR (400.16 MHz, CDCl₃) δ 9.85 (s, 1H, NH), 8.23 (d, *J* = 8.3 Hz, 1H, ArH), 7.81 (d, *J* = 7.8 Hz, 1H, ArH), 7.39 (m, 5H, ArH), 7.24 – 7.19 (m, 1H, ArH), 6.32 (s, 1H, Csp²-H), 4.23 (q, *J* = 7.1 Hz, 2H, CH₂), 1.40 (s, 9H, C(CH₃)₃), 1.29 (t, *J* = 7.1 Hz, 3H, CH₃) ppm. ¹³C NMR (100.62 MHz, CDCl₃) δ 169.8, 165.5, 150.4, 139.8, 139.4, 134.6, 133.4, 130.6, 129.0, 126.6 (2x), 125.1, 124.5, 124.2, 124.2, 123.3, 121.6, 119.4, 115.5, 84.8, 61.1, 27.4, 13.7. MS (ESI⁺): *m/z* (%) 433 ([M+H]⁺), 387, 331, 287. HMRS (ESI⁺): Calcd. for C₂₅H₂₅N₂O₅ ([M+H]⁺) 433.17580; found, 433.17562. IR (NaCl): ν 3190 (w, N-H), 2979 (w, C-H), 1735 (s, C=O), 1666 (s, C=O) cm⁻¹.

40 Biology

Cell lines. Human leukemia U937 cells were grown in RPMI medium with 10% fetal bovine serum (FBS) (Sigma), 2 mM L-glutamine (Euroclone) and antibiotics (100 U/mL penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin-B). Human breast cancer MCF7 cells were propagated in DMEM medium with 10% fetal bovine serum (FBS) (Sigma), 2 mM L-glutamine (Euroclone) and antibiotics (100 U/mL penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin-B) as previously reported.³⁵

Cell cycle and cell death analysis. These assays were performed as described.³⁶

Sirt1 assay. The Sirt1 assay was performed following the manufacturer's indications (Millipore). Briefly, This assay uses nicotinamidase to measure the nicotinamide produced upon cleavage of NAD⁺ during sirtuin-mediated deacetylation of a substrate providing a direct assessment of the activity. The use of untagged acetylated peptide can eliminate part of the potential artifacts. Sirt1 recombinant human enzyme was produced in

house following standard procedures.

60 Protein extraction. After wash, cell pellets were resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40, 10 mM NaF, 1 mM PMSF and protease inhibitor cocktail). The lysis reaction was carried out for 15 min at 4 °C. Finally, the samples were centrifuged at 13000 rpm for 30 min at 4 °C and protein concentration was quantified by Bradford assay (Bio-Rad).

Western Blot. 50 µg of proteins were loaded on 10% polyacrylamide gels. The nitrocellulose filters were stained with Ponceau red (Sigma) as additional control for equal loading. ERK1 antibody was from Santa-Cruz and P53K382ac antibody was from Millipore.

References and Notes

- For CDK's, see: (a) E. A. Sausville, D. Zaharevitz, R. Gussio, L. Meijer, M. Louarn-Leost, C. Kunick, R. Schultz, T. Lahusen, D. Headlee, S. Stinson, S. G. Arbusck and A. Senderowicz, *Pharmacol. Ther.* **1999**, *82*, 285-292. (b) C. Schultz, A. Link, M. Leost, D. W. Zaharevitz, R. Gussio, E. A. Sausville, L. Meijer and C. Kunick, *J. Med. Chem.* **1999**, *42*, 2909-2919. (c) C. Kunick, C. Schultz, T. Lemcke, D. W. Zaharevitz, R. Gussio, R. K. Jalluri, E. A. Sausville, M. Leost and L. Meijer, *Bioorg. Med. Chem. Lett.* **2000**, *10*, 567-569. (d) C. Kunick, Z. Zeng, R. Gussio, D. Zaharevitz, M. Leost, F. Totzke, C. Schächtele, M. H. G. Kubbutat, L. Meijer and T. Lemcke, *ChemBioChem* **2005**, *6*, 541-549. (e) D. P. Power, O. Lozach, L. Meijer, D. H. Grayson and S. J. Connon, *Bioorg. Med. Chem. Lett.* **2010**, *20*, 4940-4944. For PLK1 and VEGFR-2 kinases, see: (f) A.-M. Egert-Schmidt, J. Dreher, U. Dunkel, S. Kohfeld, L. Preu, H. Weber, J. E. Ehlert, B. Mutschler, F. Totzke, C. Schächtele, M. H. G. Kubbutat, K. Baumann and C. Kunick, *J. Med. Chem.* **2010**, *53*, 2433-2442. For glycogen synthase kinase-3 (GSK-3), see: (g) M. Leost, C. Schultz, A. Link, Y.-Z. Wu, J. Biernat, E.-M. Mandelkow, J. A. Bibb, G. L. Snyder, P. Greengard, D. W. Zaharevitz, R. Gussio, A. M. Senderowicz, E. A. Sausville, C. Kunick and L. Meijer, *Eur. J. Biochem.* **2000**, *267*, 5983-5994. (h) C. Kunick, K. Lauenroth, M. Leost, L. Meijer and T. Lemcke, *Bioorg. Med. Chem. Lett.* **2004**, *14*, 413-416. (i) H. Stukenbrock, R. Musmann, M. Geese, Y. Ferandin, O. Lozach, T. Lemcke, S. Kegel, A. Lomow, U. Burk, C. Dohrmann, L. Meijer, M. Austen and C. Kunick, *J. Med. Chem.* **2008**, *51*, 2196-2207.
- A. Becker, S. Kohfeld, A. Lader, L. Preu, T. Pies, K. Wiekling, Y. Ferandin, M. Knockaert, L. Meijer and C. Kunick, *Eur. J. Med. Chem.* **2010**, *45*, 335-342
- J. Trapp, A. Jochum, R. Meier, L. Saunders, B. Marshall, C. Kunick, E. Verdin, P. Goekjian, W. Sippl and M. Jung, *J. Med. Chem.* **2006**, *49*, 7307-7316.
- C. A. Lyssiotis, R. K. Foreman, J. Staerk, M. Garcia, D. Mathur, S. Markoulaki, J. Hanna, L. L. Lairson, B. D. Charette, L. C. Bouchez, M. Bollong, C. Kunick, A. Brinker, C. Y. Cho, P. G. Schultz and R. Jaenisch, *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 8912-8917.
- G. Muehlgassner, C. Bartel, W. F. Schmid, M. A. Jakupec, V. B. Arion and B. K. Keppler, *J. Inorg. Biochem.* **2012**, *116*, 180-187.
- X. Xie, T. Lemcke, R. Gussio, D. W. Zaharevitz, M. Leost, L. Meijer and C. Kunick, *Eur. J. Med. Chem.* **2005**, *40*, 655-661.
- D. W. Zaharevitz, R. Gussio, M. Leost, A. M. Senderowicz, T. Lahusen, C. Kunick, L. Meijer and E. A. Sausville, *Cancer Res.* **1999**, *59*, 2566-2569.
- (a) W. F. Schmid, S. Zorbas-Seifried, R. O. John, V. B. Arion, M. A. Jakupec, A. Roller, M. Galanski, I. Chiorescu, H. Zorbas and B. K. Keppler, *Inorg. Chem.* **2007**, *46*, 3645-3656. (b) W. F. Schmid, R. O. John, G. Muehlgassner, P. Heffeter, M. A. Jakupec, M. Galanski, W. Berger, V. B. Arion and B. K. Keppler, *J. Med. Chem.* **2007**, *50*, 6343-6355. (c) A. Dobrov, S. Goeschl, M. A. Jakupec, A. Popovic-Bijelic, A. Graeslund,

- P. Rapta and V. B. Arion, *Chem. Commun.* **2013**, *49*, 10007-10009. (d) M. F. Primik, S. Göschl, M. A. Jakupec, A. Roller, B. K. Keppler and V. B. Arion, *Inorg. Chem.* **2010**, *49*, 11084-11095.
- 9 (a) J. Ryczak, M.-A. Papini, A. Lader, A. Nasereddin, D. Kopelyanskiy, L. Preu, C. L. Jaffe and C. Kunick, *Eur. J. Med. Chem.* **2013**, *64*, 396-400. (b) C. Reichwald, O. Shimony, U. Dunkel, N. Sacerdoti-Sierra, C. L. Jaffe and C. Kunick *J. Med. Chem.* **2008**, *51*, 659-665.
- 10 10 T. Lahusen, A. De Siervi, C. Kunick and A. M. Senderowicz, *Mol. Carcinogen.* **2003**, *36*, 183-194.
- 11 D. H.-C. Chou, N. E. Bodycombe, H. A. Carrinski, T. A. Lewis, P. A. Clemons, S. L. Schreiber and B. K. Wagner, *ACS Chem. Biol.* **2010**, *5*, 729-734.
- 15 12 J. B. Bremner and W. Sengpracha, *Tetrahedron* **2005**, *61*, 5489-5498.
- 13 Z. Li, N. Lu, L. Wang and W. Zhang, *Eur. J. Org. Chem.* **2012**, *2012*, 1019-1024.
- 14 (a) J. G. Avila-Zárraga, A. Lujan-Montelongo, A. N. Covarrubias-Zuñiga and M. Romero-Ortega, *Tetrahedron Lett.* **2006**, *47*, 7987-7989. (b) L. Joucla, F. Popowycz, O. Lozach, L. Meijer and B. Joseph, *Helv. Chim. Acta* **2007**, *90*, 753-763.
- 15 D. R. Stuart, P. Alsabeh, M. Kuhn and K. Fagnou, *J. Am. Chem. Soc.* **2010**, *132*, 18326-18339.
- 25 16 O. Baudoin, M. I. Cesario, D. Guénard and F. O. Guéritte, *J. Org. Chem.* **2002**, *67*, 1199-1207.
- 17 M. Tobisu, H. Fujihara, K. Koh and N. Chatani, *J. Org. Chem.* **2010**, *75*, 4841-4847.
- 18 N. Henry, J. R. M. Blu, V. R. Bénêteau and J.-Y. Mèrou, *Synthesis* **2006**, 3895-3901.
- 30 19 H. F. Roth, M. Li, J. Jiang, D. K. Dulan and M. B. Brendan, *J. Labelled Compd. Radiopharm.* **2011**, *54*, 272-277.
- 20 S. Soto, E. Vaz, C. Dell'Aversana, R. Alvarez, L. Altucci and A. R. de Lera, *Org. Biomol. Chem.* **2012**, *10*, 2101-2112.
- 35 21 (a) C. Martínez, R. Álvarez and J. M. Aurrecoechea, *Org. Lett.* **2009**, *11*, 1083-1086. (b) C. Martínez, J. M. Aurrecoechea, Y. Madich, J. G. Denis, A. R. de Lera and R. Álvarez, *Eur. J. Org. Chem.* **2012**, 99-106. (c) Y. Madich, J. G. Denis, A. Ortega, C. Martínez, A. Matrane, L. Belachemi, A. R. de Lera, R. Alvarez and J. M. Aurrecoechea, *Synthesis* **2013**, 2009-2017.
- 40 22 R. Álvarez, C. Martínez, Y. Madich, J. G. Denis, J. M. Aurrecoechea and A. R. de Lera, *Chem. Eur. J.* **2010**, *16*, 12746-12753.
- 45 23 Y. Madich, R. Álvarez and J. M. Aurrecoechea, *Eur. J. Org. Chem.* **2014**, 6263-6271.
- 24 (a) T. C. T. Ho and K. Jones, *Tetrahedron* **1997**, *53*, 8287-8294. (b) R. Grigg, E. L. Millington and M. Thornton-Pett, *Tetrahedron Lett.* **2002**, *43*, 2605-2608.
- 50 25 Using control experiments with DMF-d₆ we discarded the possibility that indoles **9** were obtained by the reduction of palladium intermediate **II** through reaction with the solvent; see, J. A. Molina de la Torre, P. Espinet and A. C. Albéniz *Organometallics* **2013**, *32*, 5428-5434.
- 55 26 (a) V. H. Rawal and M. P. Cava, *Tetrahedron Lett.* **1985**, *26*, 6141-6142. (b) V. H. Rawal, R. J. Jones and M. P. Cava, *J. Org. Chem.* **1987**, *52*, 19-28.
- 27 K. Hiroya, S. Itoh and T. Sakamoto, *J. Org. Chem.* **2004**, *69*, 1126-1136.
- 60 28 I. P. Beletskaya and A. V. Cheprakov, *Chem. Rev.* **2000**, *100*, 3009-3066.
- 29 M. Oestreich, Ed., *The Mizoroki-Heck Reaction*, John Wiley & Sons, Chichester, 2009.
- 30 B. Laursen, M.-P. Denieul and T. Skrydstrup, *Tetrahedron* **2002**, *58*, 2231-2238.
- 65 31 B. P. Hubbard, A. P. Gomes, H. Dai, J. Li, A. W. Case, T. Considine, T. V. Riera, J. E. Lee, S. Y. E, D. W. Lamming, B. L. Pentelute, E. R. Schuman, L. A. Stevens, A. J. Y. Ling, S. M. Armour, S. Michan, H. Zhao, Y. Jiang, S. M. Sweitzer, C. A. Blum, J. S. Disch, P. Y. Ng, K. T. Howitz, A. P. Rolo, Y. Hamuro, J. Moss, R. B. Perni, J. L. Ellis, G. P. Vlasuk and D. A. Sinclair, *Science* **2013**, *339*, 1216-1219.
- 32 Y. Tang, W. Zhao, Y. Chen, Y. Zhao and W. Gu, *Cell* **2008**, *133*, 612-626.
- 75 33 J. L. Avalos, I. Celic, S. Muhammad, M. S. Cosgrove, J. D. Boeke and C. Wolberger, *Mol. Cell* **2002**, *10*, 523-535.
- 34 D. V. Kadnikov and R. C. Larock, *J. Org. Chem.* **2004**, *69*, 6772-6780.
- 35 A. Nebbioso, N. Clarke, E. Voltz, E. Germain, C. Ambrosino, P. Bontempo, R. Alvarez, E. M. Schiavone, F. Ferrara, F. Bresciani, A. Weisz, A. R. de Lera, H. Gronemeyer and L. Altucci, *Nat. Med.* **2005**, *11*, 77-84.
- 80 36 A. Nebbioso, R. Pereira, H. Khanwalkar, F. Matarese, J. García-Rodríguez, M. Miceli, C. Logie, V. Kedinger, F. Ferrara, H. G. Stunnenberg, A. R. de Lera, H. Gronemeyer and L. Altucci, *Mol. Cancer Ther.* **2011**, *10*, 2394-2404.